AbbVie Receives the MHRA’s Marketing Authorisation of Aquipta (atogepant) for the Prevention of Migraines in Adults
Shots:
- The MHRA has granted marketing authorization to Aquipta (CGRP receptor antagonist) for the prophylaxis of migraine in adults who have four migraine days per month
- The authorization was based on 2 P-III studies i.e., (ADVANCE) for episodic in a ratio (1:1:1:1) in 910 patients and (PROGRESS) for chronic migraine in a ratio (1:1:1) in 778 patients evaluating atogepant (60mg, qd) vs PBO
- In both trials, the treatment met their 1EPs of a change from baseline in mean monthly migraine days across 12wks., reductions from baseline in several secondary efficacy EPs i.e., mean monthly headache days and mean monthly acute medication days, were well tolerated. The company works with the regulatory authorities to bring the treatment to eligible patients shortly
Ref: Cision | Image: AbbVie
Related News:- AbbVie’s Aquipta (atogepant) Receives EC’s Approval for the Preventive Treatment of Migraine in Adults
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
